LOUIS TELESFORD: Open Payments
NPI 1023125523 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,364 in 221 payments from 34 companies in 2025. Trend: 2023 $5,613 · 2024 $4,501 · 2025 $4,364
Food & beverage: $4,142Education: $222
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 40 | $1,170 |
| GlaxoSmithKline, LLC. | 47 | $663 |
| ABBVIE INC. | 56 | $657 |
| Novo Nordisk Inc | 13 | $338 |
| Aimmune Therapeutics, Inc. | 6 | $151 |
| Astellas Pharma US Inc | 8 | $141 |
| Actelion Pharmaceuticals US, Inc. | 2 | $118 |
| Paratek Pharmaceuticals, Inc. | 4 | $85 |
| Merck Sharp & Dohme LLC | 3 | $77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $77 |
Products named: FARXIGA, NUCALA, VRAYLAR, BREZTRI, Wegovy, TRELEGY ELLIPTA, FASENRA, UBRELVY.
Industry payments across CT — which companies pay providers there.
